The UK's Alternative Investment Market (AIM) is experiencing a significant wave of buyouts by foreign entities, with American investors leading the charge, according to a recent analysis. In the first six months of 2026, seven companies were acquired, and another six are currently under offer, with buyers paying an average of 62 percent above the prevailing share price.
This trend indicates that UK small-cap companies are undervalued, and a weaker pound further enhances their attractiveness to international buyers. British company boards have frequently opted to accept offers rather than resist, leading to approximately £2.3 billion worth of companies leaving the market through these acquisitions.
Market Shrinkage and New Listings
The number of new companies joining AIM has fallen considerably. In the first half of 2026, only 16 firms were listed, while 30 departed, reducing the total number of companies on the market to 605. This contrasts sharply with the 2010s, when roughly 70 new companies joined AIM annually.
While £3.1 billion was raised on the market, a substantial portion, £1.9 billion, came from Rosebank Industries which subsequently upgraded to the Main Market. Despite these concerns about market contraction, trading volume has increased by 21 percent, and liquidity remains healthy at 3.9 percent.
Notable Stock Movements
In a quiet week for the broader market, the AIM All-Share index saw a modest increase of 0.6 percent, outperforming the FTSE 100. Among the week's standout performers was GCM Resources, which surged 240 percent following positive developments regarding its coal assets in Bangladesh. The Bangladeshi finance minister indicated that the country is considering coal in its energy mix, potentially including open-pit mining, which is crucial for GCM's Phulbari project.
Other significant movers included AOTI, whose shares rose 38 percent without a clear catalyst from official news, though three executives purchased shares through a staff plan. Sabien Technology climbed 36 percent after confirming progress on a UK distribution deal for its energy-saving platform. Thor Energy also saw a 33 percent jump, attributed to its managing director's upcoming presentation on natural hydrogen and helium exploration.
Declines and Sector News
Conversely, Jangada Mines experienced a 17 percent drop despite reporting high gold grades and a new discovery at its Molly Gold Project. Investors also reacted negatively to eEnergy Group, which fell 17 percent due to delays in receiving approximately £3.2 million for completed work, primarily related to solar photovoltaic installations.
In the health sector, Scancell, a British firm developing cancer treatments, could benefit from positive trial results for a rival melanoma vaccine from Moderna and Merck. The success of Moderna and Merck's approach, which uses the body's immune system to target cancer cells, validates the technology. Scancell's own treatment, an off-the-shelf vaccine, is seen as potentially more cost-effective than individually tailored therapies. The company has received UK approval to commence its own final-stage trial.